| Income Statement | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Collaboration revenue | NaN | 0 | 0 | NaN |
| Research and development | 8,181 | 11,634 | 13,143 | 13,120 |
| General and administrative | 5,090 | 4,092 | 4,399 | 4,871 |
| Total operating expenses | 13,271 | 15,726 | 17,542 | 17,991 |
| Operating loss | -13,271 | -15,726 | -17,542 | -17,991 |
| Interest income | 433 | 697 | 850 | 997 |
| Interest expense | 1,368 | 1,341 | 1,301 | 1,263 |
| Loss on extinguishment of debt | NaN | 0 | 0 | NaN |
| Other income, net | 674 | 0 | 11 | 168 |
| Total other expense | -261 | -644 | -440 | -98 |
| Net loss | -13,532 | -16,370 | -17,982 | -18,089 |
| Basic EPS | -0.28 | -0.36 | -0.4 | -0.4 |
| Diluted EPS | -0.28 | -0.36 | -0.4 | -0.4 |
| Basic Average Shares | 48,596,817 | 45,804,042 | 44,981,746 | 44,827,159 |
| Diluted Average Shares | 49,388,181 | 45,804,042 | 44,981,746 | 44,827,159 |
Werewolf Therapeutics, Inc. (HOWL)
Werewolf Therapeutics, Inc. (HOWL)